DIFFUSION PHARMACEUTICALS INC. (NASDAQ:DFFN) Files An 8-K Shareholder Director NominationsItem 5.08 Shareholder Director Nominations.
On April 11, 2017, Diffusion Pharmaceuticals Inc. (the “Company”) announced that its Board of Directors has established June 15, 2017 as the date for the Company’s 2017 Annual Meeting of Stockholders (the “Annual Meeting”) and set April 17, 2017 as the record date for the Annual Meeting. Due to the fact that the date of the Annual Meeting has been changed by more than 30 days from the anniversary date of the 2016 Annual Meeting of Stockholders, the Company is providing the due date for submission of any qualified stockholder proposal or qualified stockholder nominations.
In accordance with Rule 14a-5(f) and Rule 14a-8(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Company’s Amended and Restated Bylaws, the deadline for receipt of stockholder proposals for inclusion in the Company’s proxy statement for the Annual Meeting to Rule 14a-8 will be no later than 5:00 p.m., Eastern Time, April 21, 2017. Stockholder proposals must comply with all of the applicable requirements set forth in the rules and regulations of the Securities and Exchange Commission, including Rule 14a-8 under the Exchange Act and the Company’s Amended and Restated Bylaws.
About DIFFUSION PHARMACEUTICALS INC. (NASDAQ:DFFN)
Diffusion Pharmaceuticals Inc., formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company’s lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The Company’s Diffusion’s technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer, and brain metastases. DIFFUSION PHARMACEUTICALS INC. (NASDAQ:DFFN) Recent Trading Information
DIFFUSION PHARMACEUTICALS INC. (NASDAQ:DFFN) closed its last trading session down -0.25 at 2.90 with 152 shares trading hands.